On the other hand, “αC-OUT” inhibitors, such as vemurafenib and dabrafenib, have important clinical implications and have been observed to induce less paradoxical activation, likely due to decreased RAF/MEK interaction in this conformation.29,30,33,48 Although paradoxical activation limits the use of type I BRAFi in cancer therapy, their role is beneficial in scenarios where this activation is desired, such as wound healing,49 promoting podocytes survival,50 and here, erythropoiesis. Here, MAP2K7 is linked to cancer.